PL Developments Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: PL Developments Pharmaceutical Import Records from India — 7 Products, $18.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

PL Developments — Pharmaceutical Importer Profile (2026) | 7 Products, $18.3M Trade | TransData Nexus

PL Developments

Pharmaceutical Importer · United States · Antifungals Focus · $18.3M Total Trade · DGFT Verified

PL Developments is a pharmaceutical importer based in United States with a total trade value of $18.3M across 7 products in 6 therapeutic categories. Based on 552 verified import shipments from Indian Customs (DGFT) records, PL Developments is the #1 buyer in 3 products including Docusate, Nicotine, Miconazole. PL Developments sources from 7 verified Indian suppliers, with Encube Ethicals Private Limited accounting for 52.0% of imports.

PL Developments — Import Portfolio & Supplier Network

PL Developments import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to PL Developments?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Encube Ethicals Private Limited	$11.8M	430	52.0%
Truecare Biomedix	$5.4M	202	23.8%
Rubicon Research Private Limited	$3.7M

What Formulations Does PL Developments Import?

Formulation	Value	Ships
Sennosides & docusate sodium tablet	$1.1M	26
Abreva doco 10% crm ene 0.07 oz	$600.0K	12
Nicotine pol mini loz 4MG 20000 cherry	$563.6K	15
Acetaminophen & diphenhydramine hcl	$518.5K	14
Miconazole nitrate 2% vaginal cream	$513.8K	13
Nicotine pol loz 2MG 4000 cherry pld	$500.0K	10
Sennosides tablet 8.6MG (brown) Each	$420.3K	12
Miconazole nitrate 2 % vaginal cream	$301.7K	19
Aspirin tablets USP 81MG Each film	$284.2K	10
Bacitracin zinc ointment 1 oz/28 GM	$254.3K	9
40085 nicotine pol loz 4MG 4000 cherry	$250.0K	5
Clotrimazole 1% cream 45GM tube with 1	$223.6K	12
Sennosides & docusate sodium tablet 8.6MG/50MG (red) other details as per inv	$213.2K	6
Sennosides & docusate sodium tablet 8.6MG/50MG (red)	$213.1K	5
Sennosides & docusate sodium tablet 8.6MG/50MG (red) Each film coated tablet contains:sennosides USP 8.6MG as per	$205.0K	6

PL Developments imports 361 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Docusate	Gastrointestinal	$5.0M	99	53.4%	1
2	Nicotine	Other	$4.7M	94	31.5%	1
3	Miconazole	Antifungals	$4.7M	159	23.7%	1
4	Diphenhydramine	Antihistamines & Allergy	$1.1M	42	3.6%	7
5	Clotrimazole	Antifungals	$1.1M	72	1.2%	8
6	Aspirin	Analgesics & Antipyretics	$995.7K	54	2.6%	6
7	Zinc	Vitamins & Supplements	$686.4K	32	0.9%	16

PL Developments imports 7 pharmaceutical products across 6 categories into United States totaling $18.3M. The company is the #1 buyer for 3 products: Docusate, Nicotine, Miconazole.

PL Developments — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

PL Developments (PLD) is a prominent manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer healthcare goods in the United States. Established in 1988, the company has grown to serve nearly every major retailer in the U.S. and many globally, offering a diverse range of health and wellness products.

Headquartered in Westbury, New York, PLD operates state-of-the-art facilities across multiple locations, including California, Florida, and South Carolina. These facilities encompass over 2 million square feet, housing more than 1,600 dedicated employees. The company's comprehensive services span product development, manufacturing, packaging, and distribution, all conducted under strict FDA guidelines and current Good Manufacturing Practices (cGMP) to ensure product quality and safety.

2Distribution Network

PL Developments boasts an extensive distribution network facilitated by its strategically located facilities in New York, California, Florida, and South Carolina. These state-of-the-art, cGMP-compliant facilities enable efficient manufacturing and packaging of a wide array of pharmaceutical products. The company's logistics capabilities are designed to support a vast portfolio of over 2,000 unique stock-keeping units (SKUs), ensuring timely and reliable delivery to major retailers across the United States and internationally.

3Industry Role

In the United States pharmaceutical supply chain, PL Developments functions primarily as a contract manufacturer and distributor. While it does not operate as a wholesaler or parallel importer, PLD plays a crucial role in the production and distribution of OTC pharmaceutical products and consumer healthcare goods. By partnering with various brands, PLD manufactures and packages products that are then marketed and sold under those brands, thereby contributing significantly to the availability and accessibility of healthcare products in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — PL Developments

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

PL Developments' sourcing strategy exhibits a high degree of concentration, with a significant portion of its imported pharmaceutical products originating from India. Between 2022 and 2026, PLD imported finished pharmaceutical formulations valued at $18.3 million from India, encompassing 552 shipments and 361 unique formulations across seven products and six therapeutic categories. The top five imported products—Docusate, Nicotine, Miconazole, Diphenhydramine, and Clotrimazole—accounted for 90.8% of the total import value, indicating a strong reliance on a limited number of products. This concentration suggests that PLD's sourcing strategy is both a strategic choice to leverage cost efficiencies and a potential risk due to dependency on a narrow product range.

The shipment data reveals a stable relationship with key Indian suppliers, notably ENCUBE ETHICALS PRIVATE LIMITED, TRUECARE BIOMEDIX, and RUBICON RESEARCH PRIVATE LIMITED, which together supplied 92.2% of the total import value. The substantial number of shipments from these suppliers indicates consistent and reliable sourcing practices. However, the high concentration also exposes PLD to potential supply chain disruptions, such as production delays or regulatory challenges in India, which could impact the availability of critical products.

2Supply Chain Resilience

PL Developments' supply chain resilience is closely tied to its sourcing concentration from Indian suppliers. The company's reliance on a limited number of suppliers for key products suggests a streamlined procurement process but also highlights potential vulnerabilities. The absence of backup suppliers for these critical products indicates a lack of diversification, which could pose risks in the event of supply chain disruptions. Additionally, the limited number of unique formulations imported suggests a focused product strategy, which may limit the company's ability to adapt to changing market demands or regulatory requirements.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all drugs imported into the U.S. meet standards for quality, safety, and effectiveness, and that they are not adulterated or misbranded.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FD&C Act), which outlines the requirements for drug approval, labeling, and manufacturing practices. The FDA's Regulatory Procedures Manual provides detailed guidance on import operations and actions, including the examination and analysis of imported drugs to determine their admissibility into the U.S. market.

The marketing authorization pathway for Indian generics involves obtaining approval from the FDA through the Abbreviated New Drug Application (ANDA) process. This process requires demonstrating that the generic product is bioequivalent to the reference listed drug and meets all FDA standards for quality, safety, and efficacy. Additionally, Indian manufacturers must comply with FDA inspections and adhere to current Good Manufacturing Practices (cGMP) to ensure product quality and regulatory compliance.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must file an entry notice and an entry bond with U.S. Customs and Border Protection, notifying the FDA of the product's arrival. The FDA then reviews the shipment to determine its admissibility based on compliance with U.S. regulations.

PL Developments — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

PL Developments' product strategy focuses on a select range of therapeutic areas, including antifungals, gastrointestinal treatments, and other categories.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — PL Developments

What products does PL Developments import from India?

PL Developments imports 7 pharmaceutical products across 6 categories. Top imports: Docusate ($5.0M), Nicotine ($4.7M), Miconazole ($4.7M), Diphenhydramine ($1.1M), Clotrimazole ($1.1M).

Who supplies pharmaceuticals to PL Developments from India?

PL Developments sources from 7 verified Indian suppliers. The primary supplier is Encube Ethicals Private Limited (52.0% of imports, $11.8M).

What is PL Developments's total pharmaceutical import value?

PL Developments's total pharmaceutical import value from India is $18.3M, based on 552 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does PL Developments focus on?

PL Developments imports across 6 categories. The largest: Antifungals (31.8%), Gastrointestinal (27.1%), Other (25.7%).

Get Full PL Developments Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.